PFBC and dystonia: description of a cohort and peculiar cases
Objective: To describe dystonia in a PFBC cohort Background: Primary familial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by calcium deposition in basal…An Algorithmic Approach to Assessing Cognitive Functioning in Individuals with REM Sleep Behavior Disorder
Objective: To apply an algorithmic approach to interpretation of cognitive data to assess cognitive impairment in RBD participants. Background: Cognitive changes in emerging neurodegenerative disease…DaT-Scans Have Limited Utility in Predicting Treatment Response to Ventriculoperitoneal Shunts in Normal Pressure Hydrocephalus
Objective: To determine usefulness of DaT-SPECT imaging in the management of normal pressure hydrocephalus (NPH). Background: Dopamine transporter single-photon emission computed tomography (DaT-SPECT) imaging is…Subjective cognitive complaints in participants of the Healthy Brain Ageing (HeBA) study
Objective: To investigate the prevalence of subjective cognitive complaints (SCC) from Healthy Brain Ageing Study (HeBA) participants in Luxembourg, and explore risk factors prevalence which…Olfactory neurons’ Substance P is highly expressed in Parkinson’s disease reflecting gastrointestinal dysfunction
Objective: To elucidate the role of Substance P in PD through molecular characterization of patients’ olfactory neurons. Background: Substance P is a neuropeptide largely expressed…Incidence of childhood trauma in patients with functional movement disorder and its impact on motor symptoms severity
Objective: To assess the impact of self-reported childhood traumatic experience on motor symptoms severity in a group of patients with functional movement disorder (FMD). Background:…Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…Continuous algorithmic insights into PD motor symptoms and individual treatment response
Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…
- « Previous Page
- 1
- …
- 303
- 304
- 305
- 306
- 307
- …
- 1554
- Next Page »